Sermorelin for sleep rests on real biology and very little proof. Your deepest sleep and your body's biggest growth-hormone pulse tend to arrive together, and GHRH, the brain hormone sermorelin copies, deepened sleep in some small one-night lab experiments. But the one trial that gave older adults sermorelin every night to treat age-related sleep problems didn't find better sleep. Its early results showed slightly worse sleep scores. No published trial has shown that sermorelin treats insomnia.
The gap between those two findings is the real story.
Why people try sermorelin for sleep
Growth hormone comes out in bursts, and the biggest one of the day usually lands soon after you fall asleep. In a classic 1968 study, researchers drew blood every 30 minutes across 38 nights in eight young adults. In seven of them, a large growth-hormone peak appeared with the start of deep sleep and lasted 1.5 to 3.5 hours. When sleep was delayed, the peak moved with it (Takahashi et al., Journal of Clinical Investigation, 1968).
Deep sleep here means slow-wave sleep, the stage when brain waves on a sleep recording turn slow and large. It's the hardest stage to wake someone from.
The signal behind that pulse is growth hormone-releasing hormone, or GHRH, made at the base of the brain. Sermorelin is a shortened copy of it, the first 29 of GHRH's 44 building blocks, and it asks the pituitary gland to release growth hormone. That shared pathway is why people connect sermorelin and sleep, and why sermorelin is usually scheduled near bedtime.
The link isn't a simple switch, though. When researchers blocked GHRH receptors overnight in healthy young men, the blocker cut growth hormone's response to GHRH by more than 90%, yet slow-wave sleep didn't change (Jessup et al., European Journal of Endocrinology, 2004). A 2025 mouse study even found that growth hormone excites a wake-promoting cluster of brain cells, a built-in brake that nudges the body back toward waking (Ding et al., Cell, 2025). More growth hormone doesn't automatically mean more sleep.
GHRH and slow-wave sleep: what the sleep-lab studies found
Most of the human evidence comes from sleep labs in the 1990s and 2000s. Volunteers slept wired to monitors while researchers gave GHRH through a vein (IV) or up the nose, usually for one night, and compared it with a placebo night. They tracked slow-wave sleep and REM sleep, the dreaming stage.
| Study | Who | How GHRH was given | What changed |
|---|---|---|---|
| Steiger, 1992 | 7 healthy men | Four IV doses, 10 p.m. to 1 a.m. | Slow-wave sleep rose from about 14% to 20% of the night |
| Marshall, 1996 | Healthy volunteers | Four IV pulses vs a steady IV drip | Pulses raised slow-wave and REM sleep; the steady drip didn't |
| Kerkhofs, 1993 | Healthy young men | One IV dose at different points in the night | An early-night dose raised REM sleep, not deep sleep; a late-night dose raised deep sleep almost tenfold |
| Guldner, 1997 | 13 adults, average age 69 | Four IV doses | Fewer awakenings, but a much weaker effect than in young people |
| Perras, 1999 | 12 young and 11 older men | Nasal spray 30 minutes before bed | More slow-wave and REM sleep, mostly late in the night |
| Mathias, 2007 | Healthy young women | Four IV doses | Sleep got worse: less REM at the lower dose, less of the deepest stage at the higher one |
Two patterns stand out. First, rhythm mattered: pulses helped where a steady drip didn't, and not every lab saw an effect. A Pittsburgh study that gave GHRH to young men at or just before sleep onset found no major change in sleep (Kupfer et al., Sleep, 1991).
Second, who you are mattered. The effect was weaker in older adults, the people most likely to ask about sermorelin for sleep, and GHRH made young women's sleep worse. And none of these studies tested sermorelin the way it's prescribed today: an injection under the skin, night after night.
What about other growth-hormone peptides for sleep?
Sermorelin isn't the only prescription on this pathway. CJC-1295 is a longer-acting GHRH analogue, and ipamorelin works through a different door, the ghrelin receptor. They're often prescribed together, and sermorelin versus CJC-1295 explains how the approaches differ.
For sleep, the evidence is thinner still. No published trial has measured sleep with CJC-1295 or ipamorelin at all, so picking one over sermorelin in the hope of deeper sleep would be a guess, not a finding. The peptide actually named for sleep is no stronger: DSIP's human studies are small, decades old and conflicting.
Does sermorelin help sleep? The one trial that tested it
One study did set out to test sermorelin itself as a sleep treatment. Starting in 1996, University of Washington researchers gave healthy older men and women with age-related sleep problems either a placebo or a nightly under-the-skin injection of Geref, the brand-name sermorelin of the time, for about five months (trial record NCT00000380; Vitiello et al., Dialogues in Clinical Neuroscience, 2001).
The hormones responded: in men, 24-hour growth-hormone output roughly doubled, and IGF-1, a blood marker of growth-hormone activity, rose about 40%. Sleep didn't follow. In the preliminary results, scores on the Pittsburgh Sleep Quality Index, a standard questionnaire where a higher score means worse sleep, rose from 4.1 to 5.4 in the 37 people on sermorelin. On placebo they barely moved, from 4.5 to 4.6 in 38 people. The researchers called the change very small and possibly nonspecific.
The registry lists no posted results. But a 2008 review co-written by one of the trial's investigators summed it up: the nightly injections did not improve deep sleep and may even have reduced it, even though IGF-1 rose (Hersch and Merriam, Clinical Interventions in Aging, 2008).
Why would the lab and the trial disagree? The 2001 report offers a clue: each evening shot produced one large burst of growth hormone rather than the natural run of pulses, and late-night growth hormone fell below where it started. The lab work found that pulses mattered. That fits, but it's a clue, not a proof.
A 16-week trial of a modified cousin, Nle27-GHRH(1-29), which is not sermorelin itself, also found no change in sleep quality in 19 older women and men (Khorram et al., Journal of Clinical Endocrinology & Metabolism, 1997).
As of September 22, 2026, the day this article was written, a PubMed search turned up no published trial showing that sermorelin treats insomnia, and ClinicalTrials.gov listed no recruiting or active study of sermorelin for sleep.
Sermorelin and insomnia: the causes a provider looks at first
Most poor sleep has causes a growth-hormone signal doesn't touch: stress, pain, sleep apnea (breathing that repeatedly stops and starts during sleep), hot flashes, shift work, some medicines. Alcohol does double damage, because it also blunts the nighttime growth-hormone pulse; sermorelin and alcohol explains how.
For chronic insomnia, the American College of Physicians recommends cognitive behavioral therapy for insomnia (CBT-I), a structured program that retrains sleep habits and the thoughts that keep people awake, as the first treatment for adults (Qaseem et al., Annals of Internal Medicine, 2016).
So when a sermorelin request mentions sleep, the review usually starts with the sleep problem itself: how long it has lasted, whether there's snoring or gasping, and what else is being taken. The same gap between hormone levels and felt results runs through sermorelin for men, where sleep didn't reliably improve either.
Where sermorelin stands, and how prescribing works
No FDA-approved sermorelin product is currently marketed. Geref's treatment version was approved in 1997 and withdrawn in 2009, and the compounded formulation offered here is not FDA-approved. FDA later determined that Geref was not withdrawn for reasons of safety or effectiveness; its maker had discontinued it (Federal Register, March 4, 2013).
The one real sermorelin sleep trial used Geref. It can't describe how today's compounded formulation, prepared by a licensed U.S. compounding pharmacy, behaves.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies. When sleep is the main reason for asking, the review weighs the evidence above and the other causes of poor sleep, and a provider may decline.